<code id='ACE4205CBE'></code><style id='ACE4205CBE'></style>
      • <acronym id='ACE4205CBE'></acronym>
      <center id='ACE4205CBE'><center id='ACE4205CBE'><tfoot id='ACE4205CBE'></tfoot></center><abbr id='ACE4205CBE'><dir id='ACE4205CBE'><tfoot id='ACE4205CBE'></tfoot><noframes id='ACE4205CBE'>
      • <optgroup id='ACE4205CBE'><strike id='ACE4205CBE'><sup id='ACE4205CBE'></sup></strike><code id='ACE4205CBE'></code></optgroup>
        5. <b id='ACE4205CBE'><label id='ACE4205CBE'><select id='ACE4205CBE'><dt id='ACE4205CBE'><span id='ACE4205CBE'></span></dt></select></label></b><u id='ACE4205CBE'></u>
          <i id='ACE4205CBE'><strike id='ACE4205CBE'><tt id='ACE4205CBE'><pre id='ACE4205CBE'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-10-04 07:21:54 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：519
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          A single drug, study failures leave Anavex with nothing but cash
                                
                            
          Next article：  
                                      
                                          Peter Hotez and the public health issue of online harassment
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles